Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Pharmacy | Monthly Briefing

Back to Journal Articles

June 2011 Briefing - Pharmacy

Last Updated: July 01, 2011.

 

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 

Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for June 2011. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Bottles of Tylenol Recalled

THURSDAY, June 30 (HealthDay News) -- The manufacturer of Tylenol is recalling one lot of U.S.-distributed Tylenol Extra Strength Caplets 225 count bottles, according to an announcement by the U.S. Food and Drug Administration.

www.tylenol.com
More Information

Pain Is a Public Health Issue and Economic Burden in U.S.

THURSDAY, June 30 (HealthDay News) -- An integrated approach that responds to all the factors influencing pain can successfully treat, manage, and prevent chronic pain, according to a report published in June by the Institute of Medicine (IOM), on behalf of the National Institutes of Health (NIH).

Report

Rapamycin Offers Potential Treatment for HGPS

THURSDAY, June 30 (HealthDay News) -- Treatment with rapamycin abolishes characteristic nuclear defects, prolongs cellular life span, and improves the turnover of progerin in cultured Hutchinson-Gilford Progeria Syndrome (HGPS) fibroblasts cells and may be a potential treatment for children with this genetic disorder, according to a study published in the June 29 issue of Science Translational Medicine.

Abstract
Full Text (subscription or payment may be required)

Uncertainty of Diagnosis Tied to Increased Patient Anxiety

THURSDAY, June 30 (HealthDay News) -- Women awaiting diagnostic breast biopsy or invasive treatment experience increased stress levels, but only those awaiting biopsy have increased anxiety, according to a study published in the July issue of Radiology.

Abstract
Full Text (subscription or payment may be required)

Silodosin Found to Reduce Chronic Prostatitis Symptoms

WEDNESDAY, June 29 (HealthDay News) -- Silodosin may provide symptomatic relief and improve quality of life for patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), according to a study published in the July issue of The Journal Of Urology.

Abstract
Full Text

Flu Vaccine Safe for Sunitinib, Sorafenib Treated Patients

TUESDAY, June 28 (HealthDay News) -- Patients undergoing chemotherapy with sunitinib or sorafenib develop seroprotection rates similar to healthy controls following vaccination against influenza, according to a study published online June 28 in Clinical Cancer Research.

Abstract
Full Text (subscription or payment may be required)

Neurontin Study Deemed Seeding Trial, Not Scientific Study

TUESDAY, June 28 (HealthDay News) -- The Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) trial had extensive marketing objectives, and may have been a seeding trial to promote gabapentin and increase prescribing among health care professionals, according to a study published in the June 27 issue of the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Prophylactic Heparin May Not Prevent Placental Insufficiency

MONDAY, June 27 (HealthDay News) -- Women at risk of placental insufficiency who are treated with unfractionated heparin (UFH) during pregnancy may not have significantly better outcomes than those undergoing standard care, according to a study published online June 20 in the Journal of Thrombosis and Haemostasis.

Abstract
Full Text (subscription or payment may be required)

Simvastatin Tops Ezetimibe for Endothelial Protection

FRIDAY, June 24 (HealthDay News) -- Simvastatin is more effective than ezetimibe in treating patients with high cholesterol levels, but treatment with a combination is most beneficial, according to a study published online May 30 in the Journal of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

FDA Changes Erythropoiesis-Stimulating Agent Dosing

FRIDAY, June 24 (HealthDay News) -- The U.S. Food and Drug Administration has recommended more conservative dosing guidelines for the use of erythropoiesis-stimulating agents (ESAs) in the treatment of anemia associated with chronic kidney disease, as these drugs are tied to an increased risk of cardiovascular events.

More Information

New Drug Targets Found for Benign Prostatic Hyperplasia

THURSDAY, June 23 (HealthDay News) -- Novel drug targets, including muscarinic receptor or P2X1-purinoceptor antagonists, are potentially effective treatment options for benign prostatic hyperplasia (BPH), according to a review published online June 8 in the British Journal of Pharmacology.

Abstract
Full Text (subscription or payment may be required)

Higher Antibiotic Use Among Younger Home Care Patients

THURSDAY, June 23 (HealthDay News) -- Home care patients younger than 65 years and those with poor health are more likely to receive antibiotic treatment, according to a study published in the July issue of Infection Control and Hospital Epidemiology.

Abstract
Full Text (subscription or payment may be required)

Statin Therapy Tied to Lower Prostate Cancer Risk

THURSDAY, June 23 (HealthDay News) -- Statin therapy may decrease the risk and severity of prostate cancer, according to a study published in the July issue of The Journal of Urology.

Abstract
Full Text (payment or subscription may be required)

Topical Tacrolimus May Provide Temporary Relief for CLE

THURSDAY, June 23 (HealthDay News) -- Topical application of tacrolimus 0.1 percent ointment may provide temporary relief for acute, edematous, non-hyperkeratotic lesions in patients with cutaneous lupus erythematosus (CLE), according to a study published in the July issue of the Journal of the American Academy of Dermatology.

Abstract
Full Text (subscription or payment may be required)

Variability Seen in Primary Care High-Risk Prescribing

WEDNESDAY, June 22 (HealthDay News) -- High-risk prescribing or potentially inappropriate prescribing of drugs in primary care patients shows considerable unexplained variation between practices, and it is more likely in patients prescribed long-term drugs, according to a study published online June 21 in BMJ.

Abstract
Full Text

Telaprevir Linked to Sustained Virologic Response in Hep C

WEDNESDAY, June 22 (HealthDay News) -- The addition of telaprevir to peginterferon and ribavirin is associated with significantly improved and sustained virologic response in patients with hepatitis C virus (HCV) genotype 1 infection who have not received previous treatment, or have a history of failed viral eradication, according to two studies published in the June 23 issue of the New England Journal of Medicine.

Full Text - Jacobson (subscription or payment may be required)
Full Text - Zeuzem (subscription or payment may be required)

AbobotulinumtoxinA Beneficial for Lateral Orbital Rhytid

WEDNESDAY, June 22 (HealthDay News) -- Commercially available botulinum neuromodulator, abobotulinumtoxinA, is significantly superior to onabotulinumtoxinA in the treatment of lateral orbital rhytids, according to a study published online June 20 in the Archives of Facial Plastic Surgery.

Abstract
Full Text

Insufficient Evidence for Pretesting TPMT Status

WEDNESDAY, June 22 (HealthDay News) -- There is insufficient evidence to support pretesting for thiopurine S-methyltransferase (TPMT) status before initiating thiopurine treatment, and estimates of the sensitivity of genotyping are imprecise, according to a review published in the June 21 issue of the Annals of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Antirheumatic Drugs Linked to Lower Diabetes Risk

TUESDAY, June 21 (HealthDay News) -- Treatment of rheumatoid arthritis (RA) or psoriasis with biologic disease-modifying antirheumatic drugs (DMARDs), such as tumor necrosis factor (TNF) inhibitors, methotrexate, and hydroxychloroquine, may reduce the risk of newly recorded diabetes mellitus (DM), according to a study published in the June 22/29 issue of the Journal of the American Medical Association.

Abstract
Full Text
Editorial (subscription or payment may be required)

Intensive-Dose Statins Linked to Increased Diabetes Risk

TUESDAY, June 21 (HealthDay News) -- Intensive-dose statin therapy may be associated with an increased risk of new-onset diabetes and a lower risk of cardiovascular events, according to a meta-analysis published in the June 22/29 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)

Anti-TNF Doesn't Increase Complication Risk in Early RA

TUESDAY, June 21 (HealthDay News) -- Patients with early rheumatoid arthritis (RA) who are treated with anti-tumor necrosis factor (anti-TNF) therapy do not have an increased risk of serious infections and malignancies compared to those treated with methotrexate (MTX), according to a meta-analysis published in the June issue of Arthritis & Rheumatism.

Abstract
Full Text (subscription or payment may be required)

Millions in U.S. Do Not Receive PAD Prevention Therapies

TUESDAY, June 21 (HealthDay News) -- Millions of U.S. adults with peripheral artery disease (PAD) may not be receiving secondary prevention therapies, despite the fact that treatment with multiple agents is significantly correlated with lower all-cause mortality, according to a study published online June 20 in Circulation.

Abstract
Full Text (subscription or payment may be required)

Early Statin Therapy May Reduce Unstable Angina

TUESDAY, June 21 (HealthDay News) -- Early statin therapy following acute coronary syndromes (ACS) may reduce the risk of unstable angina at four months, but does not significantly reduce the risk of all-cause mortality, myocardial infarction (MI), or stroke, according to a review published in the June issue of the Cochrane Database of Systematic Reviews.

Abstract
Full Text (subscription or payment may be required)

Cancer Survivors Have Increased Medical Expenses

TUESDAY, June 21 (HealthDay News) -- The increased expenditure attributable to cancer applies to all cancer survivors, including longer-term survivors, according to a study published in the June 15 issue of Cancer.

Abstract
Full Text (subscription or payment may be required)

Etanercept May Be a Treatment Option for Dermatomyositis

TUESDAY, June 21 (HealthDay News) -- Etanercept appears safe with a steroid sparing effect in the treatment of dermatomyositis, according to a study published online June 17 in the Annals of Neurology.

Abstract
Full Text (subscription or payment may be required)

Long-Acting Reversible Contraceptives Safe for Most

TUESDAY, June 21 (HealthDay News) -- Long-acting reversible contraceptives (LARC) are safe and effective for almost all women of reproductive age, according to an American College of Obstetricians and Gynecologists (ACOG) practice bulletin published in the July issue of Obstetrics & Gynecology.

Abstract
Full Text (subscription or payment may be required)

Abuse-Resistant Oxycodone Approved

MONDAY, June 20 (HealthDay News) -- Oxecta, an abuse-resistant form of the top-selling painkiller oxycodone, has been approved by the U.S. Food and Drug Administration.

oxycodone

Generic Versions of Levofloxacin Approved

MONDAY, June 20 (HealthDay News) -- The first generic versions of levofloxacin, prescribed under the brand name Levaquin, have been approved by the U.S. Food and Drug Administration.

National Library of Medicine

FDA to Step Up Inspection of Imported Foods and Drugs

MONDAY, June 20 (HealthDay News) -- The U.S. Food and Drug Administration has announced a new strategy to ensure the safety and quality of drug and food products imported from other countries. The new strategy is outlined in a special report, "Pathway to Global Product Safety and Quality."

More Information

Outpatient Anticoagulant Therapy Benefits PE Patients

FRIDAY, June 15 (HealthDay News) -- Outpatient treatment with anticoagulants may be effective and safe for patients with pulmonary embolism (PE) who are selected based on predefined criteria, according to a study published online June 4 in the Journal of Thrombosis and Haemostasis.

Abstract
Full Text (subscription or payment may be required)

Coffee May Improve Virologic Response to Hep C Treatment

FRIDAY, June 17 (HealthDay News) -- Patients receiving hepatitis C therapy who drink three or more cups of coffee per day are more likely to respond to treatment compared to nondrinkers, according to a study published the June issue of Gastroenterology.

Abstract
Full Text

HPV Vaccination Program Tied to Fewer Cervical Abnormalities

FRIDAY, June 17 (HealthDay News) -- The incidence of high-grade cervical abnormalities (HGAs) has decreased in girls younger than 18 years, within three years of the implementation of a population-wide human papillomavirus (HPV) vaccination program in Australia, according to a review published in the June 18 issue of The Lancet.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

FDA: Smoking Cessation Drug Tied to Cardiac Issues

FRIDAY, June 17 (HealthDay News) -- The U.S. Food and Drug Administration has warned consumers and health care professionals that varenicline (Chantix) may be associated with a small but increased risk of cardiovascular adverse events in individuals with cardiovascular disease.

More Information

FDA: Diabetes Drug May Up Risk of Bladder Cancer

THURSDAY, June 16 (HealthDay News) -- The U.S. Food and Drug Administration has warned consumers and health care professionals that pioglitazone (Actos) may increase the risk of bladder cancer when used for more than one year.

More Information

Nulojix Approved to Help Thwart Kidney Rejection

THURSDAY, June 16 (HealthDay News) -- Nulojix (belatacept) has been approved by the U.S. Food and Drug Administration to prevent rejection of a transplanted kidney in adults.

kidney transplant

Flecainide Treatment Linked to Sudden Cardiac Death

THURSDAY, June 16 (HealthDay News) -- Patients with atrial fibrillation (AF) treated with flecainide develop an increased risk of sudden cardiac death (SCD) or proarrhythmic events, according to a study published online June 2 in the Journal of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

Multifactorial Causes Linked to Increasing Opioid Deaths

THURSDAY, June 16 (HealthDay News) -- Opioid-related deaths occur due to multifactorial causes, and solutions are required to address all the causes, according to a review published online June 13 in a supplement of Pain Medicine.

Abstract
Full Text

New Meningococcal A Conjugate Vaccine Is Effective

WEDNESDAY, June 15 (HealthDay News) -- A new meningococcal A (MenA) conjugate vaccine (PsA-TT) has been found to have a stronger antibody response to group A meningococci than a quadrivalent polysaccharide reference vaccine (PsACWY), according to a study published in the June 16 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)

New Rotavirus Vaccine Reduces Cases of Infant Diarrhea

WEDNESDAY, June 15 (HealthDay News) -- In Mexico and Brazil, use of the new monovalent rotavirus vaccine (RV1) is associated with a short-term risk of intussusception in vaccinated infants but prevents a far higher number of hospitalizations and deaths from diarrhea, according to a study published in the June 16 issue of the New England Journal of Medicine.

Abstract
Full Text
Editorial

Increased Mortality Risk Linked to Use of Mist Inhaler

WEDNESDAY, June 15 (HealthDay News) - Patients with chronic obstructive pulmonary disease who use a tiotropium mist inhaler may have an increased risk of mortality, according to a review published online June 14 in BMJ.

Abstract
Full Text
Editorial (subscription or payment may be required)

Increased Recurrent Stroke Risk in Type 2 Diabetes

WEDNESDAY, June 15 (HealthDay News) -- Patients enrolled in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial who have type 2 diabetes may have increased incidence of recurrent stroke and cardiovascular events, but the effect of atorvastatin treatment is independent of whether the patients have type 2 diabetes, or metabolic syndrome (MetS), according to a study published online June 13 in the Archives of Neurology.

Abstract
Full Text (subscription or payment may be required)

Increased Spending Seen for Glaucoma Medications in U.S.

WEDNESDAY, June 15 (HealthDay News) -- Expenditures on glaucoma medications increased significantly in the United States from 2001 to 2006, especially among women, those with public-only insurance, and those with less than a high school education, according to a study published online June 13 in the Archives of Ophthalmology.

Abstract
Full Text (subscription or payment may be required)

Life Expectancy in U.S. Counties Below Many Nations

WEDNESDAY, June 15 (HealthDay News) -- Most counties within the United States fall behind the international frontier with the best life expectancies in the world, according to a study published online June 15 in Population Health Metrics.

Abstract
Full Text

Inappropriate Medicines Tied to Serious Avoidable Adverse Events

WEDNESDAY, June 15 (HealthDay News) -- Use of the Screening Tool of Older Persons' potentially inappropriate prescriptions (STOPP) criteria has identified an association between potentially inappropriate medicine (PIM) prescriptions and the likelihood of a serious adverse drug event (ADE) in older people; and, when hospitalized, older people are at risk of being prescribed PIMs and actually inappropriate medicines (AIMs), especially in intensive care units (ICUs), according to a study and research letter published in the June 13 issue of the Archives of Internal Medicine.

Abstract - Hamilton
Full Text (subscription or payment may be required)
Abstract - Morandi
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

FDA OKs Test to Spot HER2-Positive Breast Cancer

TUESDAY, June 14 (HealthDay News) -- The U.S. Food and Drug Administration has approved the Inform Dual ISH test, a genetic test to determine whether women with breast cancer are human epidermal growth factor receptor (HER)2-positive and therefore candidates for trastuzumab (Herceptin).

More Information

Ranibizumab May Reduce Impaired Vision in AMD

TUESDAY, June 14 (HealthDay News) -- Treatment of neovascular age-related macular degeneration (AMD) with ranibizumab may reduce legal blindness and visual impairment, according to a study published in the June issue of the Archives of Ophthalmology.

Abstract
Full Text

Potiga Approved for Adult Epileptic Seizures

MONDAY, June 13 (HealthDay News) -- Potiga (ezogabine) tablets have been approved by the U.S. Food and Drug Administration to treat partial epileptic seizures in adults, the agency said Monday.

Centers for Disease Control and Prevention

Photodynamic Therapy Effective in Mesothelioma

MONDAY, June 13 (HealthDay News) -- Patients with malignant pleural mesothelioma who are treated with radical pleurectomy (RP) and intraoperative photodynamic therapy (PDT) have improved overall survival compared to those treated with modified extrapleural pneumonectomy (MEPP), according to a study published in the June issue of The Annals of Thoracic Surgery.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Benzodiazepine Admissions Almost Tripled From '98 to '08

FRIDAY, June 10 (HealthDay News) -- Benzodiazepine abuse-related admissions nearly tripled from 1998 to 2008 and are accompanied by abuse of another substance in 95 percent of cases, according to the Treatment Episode Data Set (TEDS) report published online June 2 by the Substance Abuse and Mental Health Services Administration (SAMHSA).

Full Text

Clopidogrel Doesn't Reduce PCI-Related Complications

FRIDAY, June 10 (HealthDay News) -- Clopidogrel pretreatment for patients undergoing elective percutaneous coronary intervention (PCI), with bivalirudin as the planned anticoagulant, is not associated with a reduced risk of PCI-related complications, according to a study published in the June 15 issue of The American Journal of Cardiology.

Abstract
Full Text (subscription or payment may be required)

IMS: New Recommendations on HRT Use Released

FRIDAY, June 10 (HealthDay News) -- Hormone replacement therapy (HRT) should be given according to the needs of individual menopausal women, after assessing the benefits and risks, severity of symptoms, age, and family history; this is according to the recommendations of the International Menopause Society (IMS), published online June 10 in Climacteric to coincide with presentation at the 13th World Congress on Menopause, held from June 8 to 11 in Rome.

Full Text (subscription or payment may be required)

Prostate Drugs Undergo Label Revision Due to Cancer Risk

THURSDAY, June 9 (HealthDay News) -- Drugs in the class of 5-alpha reductase inhibitors (5-ARIs), which includes finasteride and dutasteride, have undergone a label change to reflect current safety information concerning an increased risk of high-grade prostate cancer, the U.S. Food and Drug Administration has announced.

More Information

Most Parents Vaccinate Their Children Despite Concerns

THURSDAY, June 9 (HealthDay News) -- Although the majority of U.S. parents vaccinate their children, most have questions and concerns, according to a study published in the June issue of Health Affairs.

Abstract
Full Text (subscription or payment may be required)

Simvastatin Plus Ezetimibe Effective in Kidney Disease

THURSDAY, June 9 (HealthDay News) -- For patients with chronic kidney disease, lowering of low density lipoprotein (LDL) cholesterol with simvastatin and ezetimibe may reduce the risk of major atherosclerotic events, according to a study published online June 9 in The Lancet.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Simvastatin Safety Recommendations Announced

WEDNESDAY, June 8 (HealthDay News) -- The U.S. Food and Drug Administration has notified consumers and health care providers of safety label changes to simvastatin (Zocor), as the highest approved dose of the drug (80 mg) has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

More Information

NSAID Use Linked to Increased Venous Thromboembolism Risk

WEDNESDAY, June 8 (HealthDay News) -- The use of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2-selective inhibitors (COX2Is) is associated with an increased risk of venous thromboembolism (VTE), according to a study published online May 18 in the Journal of Thrombosis and Haemostasis.

Abstract
Full Text (subscription or payment may be required)

Antiepileptic Drugs Have Dose-Dependent Tie to Birth Defects

TUESDAY, June 7 (HealthDay News) -- Four commonly used antiepileptic drugs are associated with a dose-dependent increased risk of major birth defects when used at the beginning of pregnancy, according to a study published online June 6 in The Lancet Neurology.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Adding Zoledronic Acid Improves Breast CA Survival

MONDAY, June 6 (HealthDay News) -- Adding zoledronic acid to either anastrozole or tamoxifen improves disease-free survival in women with endocrine-receptor-positive breast cancer who are receiving adjuvant endocrine therapy, according to a study published online June 4 in The Lancet Oncology.

Abstract
Full Text (subscription or payment may be required)

No Survival Benefit With Cetuximab in Colorectal Cancer

MONDAY, June 6 (HealthDay News) -- The addition of cetuximab to standard chemotherapy for the treatment of advanced colorectal cancer does not improve progression-free survival (PFS) or overall survival (OS), according to a study published online June 4 in The Lancet.

Abstract - Maughan
Full Text (subscription or payment may be required)
Abstract - Adams
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Paroxetine With Pravastatin Raises Blood Glucose Levels

MONDAY, June 6 (HealthDay News) -- Co-administration of paroxetine and pravastatin is associated with an increase in blood glucose levels, especially in patients with diabetes, according to a study published online May 25 in Clinical Pharmacology & Therapeutics.

Abstract
Full Text

More Strokes Treated With Thrombolytics in the U.S.

FRIDAY, June 3 (HealthDay News) -- The use of recombinant tissue plasminogen activator (rtPA) to treat acute ischemic stroke (AIS) increased significantly between 2005 and 2009 in the United States, according to a study published online June 2 in Stroke.

Abstract
Full Text

Placebo or No Treatment Effective for Headache

FRIDAY, June 3 (HealthDay News) -- Individuals with headaches have an average recovery rate of 35.7 percent when they are in the placebo or no-treatment group of a trial, according to a review published online May 20 in the Journal of Manipulative and Physiological Therapeutics.

Abstract
Full Text (subscription or payment may be required)

FDA: Blood Pressure Drugs Not Tied to Cancer Risk

THURSDAY, June 2 (HealthDay News) -- The U.S. Food and Drug Administration has notified consumers and health care providers that angiotensin receptor blockers (ARBs) are not associated with an increased risk of developing cancer.

More Information

Timing of Ezetimibe Relative to Statin Affects Plaque Regression

THURSDAY, June 2 (HealthDay News) -- Ezetimibe may be beneficial for regressing atherosclerosis in statin-naive patients with peripheral artery disease (PAD), but when added to existing statin therapy, it may lead to atherosclerosis progression, according to a study published online May 16 in Atherosclerosis.

Abstract
Full Text (subscription or payment may be required)

Melanoma Vaccine May Enhance Interleukin-2 Efficacy

WEDNESDAY, June 1 (HealthDay News) -- Patients with advanced melanoma who are treated with interleukin-2 and melanoma vaccine may have an improved clinical response and longer survival than those treated with interleukin-2 alone, according to a study published in the June 2 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)

Fibroblast Growth Factor Not Effective in Limb Ischemia

WEDNESDAY, June 1 (HealthDay News) -- Treatment with non-viral 1 fibroblast growth factor (NV1FGF) does not reduce the risk of amputation or death in patients with critical limb ischemia, according to a study published online May 31 in The Lancet.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Corticosteroids May Shorten Pneumonia Hospital Stay

WEDNESDAY, June 1 (HealthDay News) -- Non-immunocompromised patients with community-acquired pneumonia treated with intravenous dexamethasone in addition to antibiotic therapy may have a shorter hospital stay, according to a study published online June 1 in The Lancet.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Viral Breakthrough After Nucleos(t)ide Analog Therapy

WEDNESDAY, June 1 (HealthDay News) -- Virological breakthrough (VBT) is common in patients with chronic hepatitis B (CHB) undergoing nucleos(t)ide analog (NUC) treatment, but is not always related to antiviral drug resistance, according to a study published in the May issue of Hepatology.

Abstract
Full Text (subscription or payment may be required)

Maternal Influenza Vaccination Tied to Reduced Prematurity

WEDNESDAY, June 1 (HealthDay News) -- Receipt of vaccination against influenza during any trimester of pregnancy reduces the likelihood of prematurity and of small-for-gestational-age (SGA) births during local and widespread influenza activity periods, according to a study published online May 31 in PloS Medicine.

Abstract
Full Text

Beta Blockers May Benefit Breast Cancer Patients

WEDNESDAY, June 1 (HealthDay News) -- In patients with breast cancer, beta-blockers may reduce disease progression and mortality as well as improve relapse-free survival, according to two studies published online May 31 in the Journal of Clinical Oncology.

Abstract - Barron
Full Text (subscription or payment may be required)
Abstract - Melhem-Bertrandt
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2011 ScoutNews, LLC. All rights reserved.


Previous: June 2011 Briefing - Pain Management Next: Older Breast Cancer Patients Likely to Die of Heart Disease

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.